Emerging Treatments in Type 2 Diabetes: Focus on Canagliflozin

Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s39145
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Emerging DPP-4 Inhibitors: Focus on Linagliptin for Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2013English

Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes

Clinical Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Effect of Canagliflozin on Serum Uric Acid in Patients With Type 2 Diabetes Mellitus

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Pharmacological Treatments for Type 2 Diabetes

2015English

The CANVAS Program: Implications of Canagliflozin on Reducing Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2019English

Use of DPP-4 Inhibitors in Type 2 Diabetes: Focus on Sitagliptin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2010English

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Advances in Therapy
MedicinePharmacology
2015English

The Emerging Genetic Architecture of Type 2 Diabetes

Cell Metabolism
Cell BiologyMolecular BiologyPhysiology
2008English

Emerging Small-Molecule Treatments for Multiple Sclerosis: Focus on B Cells

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy